title: Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase.
abstract: CD26 and ecto-adenosine deaminase (ADA) are found associated on the plasma membrane of T lymphocytes and each possess distinct catalytic activities. CD26 has a proteolytic activity identical to dipeptidylpeptidase IV (DPPIV; E.C. 3.4.14.5), and ecto-ADA (E.C. 3.5.4.4) degrades extracellular adenosine. The cell surface expression of CD26 and ecto-adenosine deaminase (ecto-ADA) is regulated on stimulated T lymphocytes, and ADA binding to CD26 produces a synergistic costimulatory response with T cell receptor activation. This study addresses the potential regulation by allosteric interactions of the catalytic activities of CD26 associated with ecto-ADA, which could define the mechanism of the synergism observed in T cell signaling. Cell lines genetically deficient in ADA, ligands for ADA such as adenosine, and a specific inhibitor of ADA, deoxycoformycin, were used to define the effect of ADA activity on CD26 DPPIV activity and affinity for dipeptide substrate. Conversely, a recombinant Chinese hamster ovary cell line expressing human CD26 with or without a mutation in the DPPIV catalytic domain, and the boronic acid inhibitor Val-boroPro, were used to determine the effect of DPPIV activity on ecto-ADA activity and association with CD26. These studies found no significant allosteric interaction between the catalytic activities of CD26 and ecto-ADA when associated. Therefore, signaling events in T cells involving costimulation with CD26 and ecto-ADA and the synergism observed upon ADA binding to CD26 occur independently of the catalytic activities of these cell surface molecules.
authors.affiliation: Department of Immunological Diseases, Inflammatory Diseases, and Pharmaceutics, Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877, USA.
authors.forename: D D
authors.initials: DD
authors.lastname: Jeanfavre
authors.forename: J R
authors.initials: JR
authors.lastname: Woska
authors.forename: C A
authors.initials: CA
authors.lastname: Pargellis
authors.forename: C A
authors.initials: CA
authors.lastname: Kennedy
authors.forename: J
authors.initials: J
authors.lastname: Prendergast
authors.forename: C
authors.initials: C
authors.lastname: Stearns
authors.forename: P L
authors.initials: PL
authors.lastname: Reilly
authors.forename: R W
authors.initials: RW
authors.lastname: Barton
authors.forename: B J
authors.initials: BJ
authors.lastname: Bormann
mesh_terms: D000243:Adenosine Deaminase / Q000378:metabolism*; D058892:Adenosine Deaminase Inhibitors; D000494:Allosteric Regulation; D000818:Animals; D001897:Boronic Acids / Q000494:pharmacology*; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D008214:Lymphocytes / Q000201:enzymology; D015649:Pentostatin / Q000494:pharmacology*
chemical_list: D058892:Adenosine Deaminase Inhibitors; D001897:Boronic Acids; D004791:Enzyme Inhibitors; D015649:Pentostatin; D018819:Dipeptidyl Peptidase 4; D000243:Adenosine Deaminase